Determination of 2,3-dinor-6-ketoprostaglandin F1 alpha in urine samples by liquid chromatography and radioimmunoassay. 1986

J Casas, and J Rosello, and E Gelpí, and F Guarner, and C Guarner, and J Quiroga, and I Colina, and J Prieto

A method for 2,3-dinor-6-ketoprostaglandin F1 alpha quantification based on high-performance liquid chromatography-radioimmunoassay is described. Samples are acidified to pH 3 and processed through C18 disposable cartridges. The prostanoids are eluted with methyl formate and further separated on a reversed-phase column using acetonitrile-acetic acid-triethylamine buffer (32:68). Studies of the effect of eluent pH were performed in order to optimize resolution and separation of 2,3-dinor-6-keto-PGF1 alpha from other prostanoids. Eluates were collected and assayed by radioimmunoassay using a heterologous system, with 6-keto-PGF1 alpha as radioligand and an antiserum with high cross-reactivity for 2,3-dinor-6-keto-PGF1 alpha. Sensitivity, precision and accuracy of the assay procedure are reported together with the validation of its specificity. The proposed method has been applied to the determination of this prostacyclin metabolite in human urine.

UI MeSH Term Description Entries
D008103 Liver Cirrhosis Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. Cirrhosis, Liver,Fibrosis, Liver,Hepatic Cirrhosis,Liver Fibrosis,Cirrhosis, Hepatic
D008297 Male Males
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002853 Chromatography, Liquid Chromatographic techniques in which the mobile phase is a liquid. Liquid Chromatography
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013467 Sulindac A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects. Aclin,Apo-Sulin,Arthrobid,Arthrocine,Chibret,Clinoril,Copal,Kenalin,Klinoril,MK-231,Novo-Sundac,Nu-Sulindac,Sulindal,Apo Sulin,MK 231,MK231,Novo Sundac,Nu Sulindac
D015121 6-Ketoprostaglandin F1 alpha The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue. 6-Keto-PGF1 alpha,6-Oxo-PGF1 alpha,6-Oxoprostaglandin F1 alpha,6 Ketoprostaglandin F1 alpha,6 Keto PGF1 alpha,6 Oxo PGF1 alpha,6 Oxoprostaglandin F1 alpha,F1 alpha, 6-Ketoprostaglandin,F1 alpha, 6-Oxoprostaglandin,alpha, 6-Keto-PGF1,alpha, 6-Ketoprostaglandin F1,alpha, 6-Oxo-PGF1,alpha, 6-Oxoprostaglandin F1

Related Publications

J Casas, and J Rosello, and E Gelpí, and F Guarner, and C Guarner, and J Quiroga, and I Colina, and J Prieto
August 1994, Analytical biochemistry,
J Casas, and J Rosello, and E Gelpí, and F Guarner, and C Guarner, and J Quiroga, and I Colina, and J Prieto
January 1983, Biochimica et biophysica acta,
J Casas, and J Rosello, and E Gelpí, and F Guarner, and C Guarner, and J Quiroga, and I Colina, and J Prieto
August 1994, Journal of chromatography. B, Biomedical applications,
J Casas, and J Rosello, and E Gelpí, and F Guarner, and C Guarner, and J Quiroga, and I Colina, and J Prieto
March 1984, Journal of chromatography,
J Casas, and J Rosello, and E Gelpí, and F Guarner, and C Guarner, and J Quiroga, and I Colina, and J Prieto
December 1993, Journal of chromatography,
J Casas, and J Rosello, and E Gelpí, and F Guarner, and C Guarner, and J Quiroga, and I Colina, and J Prieto
July 2000, Journal of chromatography. A,
J Casas, and J Rosello, and E Gelpí, and F Guarner, and C Guarner, and J Quiroga, and I Colina, and J Prieto
January 1991, Journal of chromatography,
J Casas, and J Rosello, and E Gelpí, and F Guarner, and C Guarner, and J Quiroga, and I Colina, and J Prieto
March 1994, Journal of chromatography. B, Biomedical applications,
J Casas, and J Rosello, and E Gelpí, and F Guarner, and C Guarner, and J Quiroga, and I Colina, and J Prieto
July 1997, Critical care medicine,
Copied contents to your clipboard!